Biogen vet jumps to CSO at Third Rock Treg biotech; Karuna CEO is stepping down, but this isn't goodbye
Just a few days into her new job, Ellen Cahir-McFarland’s office is being emptied.
Cahir-McFarland, formerly head of research at Annexon, is the new chief scientific officer of Abata Therapeutics, a preclinical biotech that’s developing regulatory T cell, or Treg, therapies for multiple sclerosis. On Monday, Abata will be moving from its current shared space to its new office in Watertown, MA — hence the emptying, Cahir-McFarland tells Endpoints News from a now bare, white-walled office room.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.